Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript May 13, 2026Milestone Pharmaceuticals Inc. misses on earnings expectations.
Milestone Pharmaceuticals Inc. (MIST)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Propel Bio Management Leen Kawas And Richard Kayne | 4,118,321 | $5,081,571 | 3.2% | |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 2,317,176 | $2,757,439 | +274% | 0% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,944,530 | $2,313,991 | +18% | 0% |
| 4. | Millennium Management Israel Englander | 1,544,325 | $1,837,747 | +284% | 0% |
| 5. | Point72 Asset Management Steve Cohen | 1,085,683 | $1,291,963 | +126% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.69 | 7,000 | $32,830.00 | 10,000 | 2022-12-05 | Filing | |
| $4.86 | 3,000 | $14,580.00 | 3,000 | 2022-12-01 | Filing | |
| $4.93 | 15,000 | $73,950.00 | 15,000 | 2022-10-19 | Filing | |
| $5.20 | 10,000 | $52,000.00 | 10,000 | 2022-10-20 | Filing | |
| $5.26 | 4,000 | $21,040.00 | 4,000 | 2022-10-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.26 | 36,500 | $82,490.00 | 446,244 | 2026-04-16 | Filing | |
| $1.93 | 12,245 | $23,632.85 | 113,181 | 2026-01-26 | Filing | |
| $2.32 | 58,007 | $134,576.24 | 105,326 | 2025-12-15 | Filing | |
| $1.93 | 12,245 | $23,632.85 | 49,848 | 2026-01-26 | Filing | |
| $2.32 | 58,007 | $134,576.24 | 41,993 | 2025-12-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,331,001 | $7,533,891 | 0.07% | |
| 2. | 2,000,025 | $2,380,030 | 0% | |
| 3. | 1,506,405 | $1,792,622 | 0.03% | |
| 4. | 750,000 | $892,500 | 0% | |
| 5. | 724,141 | $861,727 | 0% |
News See All
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects
Milestone Pharmaceuticals (NASDAQ:MIST) is one of the Canadian penny stocks to buy right now.
13 Best Canadian Penny Stocks to Buy Right Now
Penny and small-cap stocks have lagged the overall market amid heightened focus on large caps during the artificial intelligence boom.
Hedge Fund and Insider Trading News: Daniel Och, Bill Ackman, Daniel Loeb, David Einhorn, Saba Capital Management, Brookfield Asset Management, Milestone Pharmaceuticals Inc (MIST), Axcella Health Inc. (AXLA), and More
The hedge fund firm formerly known as Och-Ziff "deteriorated" under the "mismanagement" of its founder Daniel Och, forcing those who succeeded him to spend years stabilizing the Wall Street firm, the ...
10 Stocks to Buy According to Neil Shahrestani's Ikarian Capital
In this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani's Ikarian Capital.
Is Milestone Pharmaceuticals (MIST) A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a good investment right now.
Milestone Pharmaceuticals Inc. (MIST): Are Hedge Funds Right About This Stock?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Should You Avoid Milestone Pharmaceuticals Inc. (MIST)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Hedge Fund Resource Center